Something changed in antibody discovery that the field spent a decade waiting for. Antibodies designed on a computer, rather than fished from an immunized animal or a display library, are now being validated in the lab at binding rates and affinities that hold their own against molecules found the traditional way. What was a promising…
Shots:
Lilly leads with precision and purpose with 45 deals totaling $21.22B in 2025, focusing on platform-driven, science-led partnerships across oncology, gene therapy, RNA editing, and AI-enabled discovery while building durable innovation engines rather than chasing short-term wins
Strategic dealmaking over sheer volume is evident in partnerships like precision oncology with Scorpion Therapeutics and CNS delivery with Sangamo, structured to…

